Search hospitals

>

Illinois

>

Chicago

University of Illinois at Chicago

Claim this profile

Chicago, Illinois 60612

Global Leader in Cancer

Global Leader in Breast Cancer

Conducts research for Lung Cancer

Conducts research for Sickle Cell Disease

Conducts research for Brain Tumor

906 reported clinical trials

63 medical researchers

Photo of University of Illinois at Chicago in ChicagoPhoto of University of Illinois at Chicago in Chicago

Summary

University of Illinois at Chicago is a medical facility located in Chicago, Illinois. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Sickle Cell Disease, Brain Tumor and other specialties. University of Illinois at Chicago is involved with conducting 906 clinical trials across 1,229 conditions. There are 63 research doctors associated with this hospital, such as Mary L. Schmidt, Lawrence E. Feldman, Peter Riedell, MD, and Shikha Jain.

Area of expertise

1

Cancer

Global Leader

University of Illinois at Chicago has run 88 trials for Cancer. Some of their research focus areas include:

Stage IV
Stage III
Stage I
2

Breast Cancer

Global Leader

University of Illinois at Chicago has run 68 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV

Top PIs

Clinical Trials running at University of Illinois at Chicago

Breast Cancer

Lung Cancer

Prostate Cancer

Skin Cancer

Breast cancer

Multiple Myeloma

Cancer

Kidney Cancer

Pancreatic Cancer

Esophageal cancer

Image of trial facility.

Abemaciclib + Hormone Therapy

for Breast Cancer

This is a post-marketing single arm, phase IV trial in which patients with high-risk early-stage HR+HER2- breast cancer will receive adjuvant abemaciclib in combination with endocrine therapy (ET) After study intervention, participants will remain on combination abemaciclib + ET at the discretion of their treating providers

Recruiting

3 awards

Phase 4

5 criteria

Image of trial facility.

PF-07220060 + Letrozole

for Breast Cancer

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Imlunestrant

for Early Breast Cancer

This trial is testing a new medication called imlunestrant to see if it works better than standard hormone treatments for certain breast cancer patients. The study focuses on patients with early-stage breast cancer that is estrogen receptor positive and HER2 negative, who have already been on hormone therapy for a period of time and are at high risk of their cancer returning. Imlunestrant works by blocking estrogen from helping cancer cells grow.

Recruiting

2 awards

Phase 3

6 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at University of Illinois at Chicago?

Where is University of Illinois at Chicago located?

Who should I call to ask about financial aid or insurance network?

What insurance does University of Illinois at Chicago accept?

What awards or recognition has University of Illinois at Chicago received?